{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:18:53Z","timestamp":1776723533513,"version":"3.51.2"},"reference-count":184,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly type of primary malignant brain tumor, with a patient\u2019s median survival rate ranging from 15 to 17 months. The current treatment for GBM involves tumor resection surgery based on MRI image analysis, followed by radiotherapy and treatment with temozolomide. However, the gradual development of tumor resistance to temozolomide is frequent in GBM patients leading to subsequent tumor regrowth\/relapse. For this reason, the development of more effective therapeutic approaches for GBM is of critical importance. Low tumor oxygenation, also known as hypoxia, constitutes a major concern for GBM patients, since it promotes cancer cell spreading (invasion) into the healthy brain tissue in order to evade this adverse microenvironment. Tumor invasion not only constitutes a major obstacle to surgery, radiotherapy, and chemotherapy, but it is also the main cause of death in GBM patients. Understanding how hypoxia triggers the GBM cells to become invasive is paramount to developing novel and more effective therapies against this devastating disease. In this review, we will present a comprehensive examination of the available literature focused on investigating how GBM hypoxia triggers an invasive cancer cell phenotype and the role of these invasive proteins in GBM progression.<\/jats:p>","DOI":"10.3390\/cells6040045","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T10:47:38Z","timestamp":1511347658000},"page":"45","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":283,"title":["The Role of Hypoxia in Glioblastoma Invasion"],"prefix":"10.3390","volume":"6","author":[{"given":"Ana","family":"Monteiro","sequence":"first","affiliation":[{"name":"Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, Room 3.4, 8005-139 Faro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0394-6048","authenticated-orcid":false,"given":"Richard","family":"Hill","sequence":"additional","affiliation":[{"name":"Brain Tumour Research Centre of Excellence, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK"}]},{"given":"Geoffrey","family":"Pilkington","sequence":"additional","affiliation":[{"name":"Brain Tumour Research Centre of Excellence, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4856-3908","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Madureira","sequence":"additional","affiliation":[{"name":"Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, Room 3.4, 8005-139 Faro, Portugal"},{"name":"Brain Tumour Research Centre of Excellence, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK"}]}],"member":"1968","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/neuonc\/nov009","article-title":"Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525","volume":"17","author":"Wang","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ijc.26083","article-title":"Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas","volume":"129","author":"Felsberg","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","article-title":"Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis","volume":"9","author":"Phillips","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","article-title":"The NF1 somatic mutational landscape in sporadic human cancers","volume":"11","author":"Philpott","year":"2017","journal-title":"Hum. Genom."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e000144","DOI":"10.1136\/esmoopen-2016-000144","article-title":"Hallmarks of glioblastoma: A systematic review","volume":"1","author":"Poulsen","year":"2016","journal-title":"ESMO Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2017.01.010","article-title":"Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas","volume":"187","author":"Mahase","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/labinvest.3700070","article-title":"Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma","volume":"84","author":"Brat","year":"2004","journal-title":"Lab. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/0008-5472.CAN-03-2073","article-title":"Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population","volume":"64","author":"Brat","year":"2004","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W","article-title":"Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression","volume":"88","author":"Zagzag","year":"2000","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00125480-200201000-00004","article-title":"Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation","volume":"9","author":"Brat","year":"2002","journal-title":"Adv. Anat. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0002-9440(10)64025-4","article-title":"Glomeruloid microvascular proliferation orchestrated by VPF\/VEGF: A new world of angiogenesis research","volume":"158","author":"Brat","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.yexcr.2012.07.017","article-title":"Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications","volume":"318","author":"Yang","year":"2012","journal-title":"Exp. Cell Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1215\/S1152851704001115","article-title":"Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis","volume":"7","author":"Kaur","year":"2005","journal-title":"Neuro-Oncology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/neuonc\/not148","article-title":"Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome","volume":"16","author":"Jensen","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00005072-200606000-00001","article-title":"\u201cPseudopalisading\u201d necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis","volume":"65","author":"Rong","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/neup.12111","article-title":"Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1\u03b1 in human glioblastoma","volume":"34","author":"Clara","year":"2014","journal-title":"Neuropathology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2353\/ajpath.2010.091021","article-title":"Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres","volume":"177","author":"Bar","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_28","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_29","first-page":"4564","article-title":"Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows","volume":"54","author":"Yuan","year":"1994","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0940-2993(11)80292-7","article-title":"Vascular morphology and angiogenesis in glial tumors","volume":"47","author":"Plate","year":"1995","journal-title":"Exp. Toxicol. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.acra.2005.05.027","article-title":"Vessel tortuosity and brain tumor malignancy: A blinded study","volume":"12","author":"Bullitt","year":"2005","journal-title":"Acad. Radiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in brain tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fncel.2014.00418","article-title":"Gliomas and the vascular fragility of the blood brain barrier","volume":"8","author":"Dubois","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-Inducible Factors and the Response to Hypoxic Stress","volume":"40","author":"Majmundar","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1\u03b1 and HIF2\u03b1: Sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.celrep.2014.02.011","article-title":"Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia","volume":"6","author":"Zhang","year":"2014","journal-title":"Cell Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"C260","DOI":"10.1152\/ajpcell.00315.2015","article-title":"Hypoxia-inducible factor 3 biology: Complexities and emerging themes","volume":"310","author":"Duan","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"19575","DOI":"10.1074\/jbc.R200030200","article-title":"Hypoxia-inducible factor and its biomedical relevance","volume":"278","author":"Huang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrm1366","article-title":"Oxygen sensing by HIF hydroxylases","volume":"5","author":"Schofield","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.cellbio.15.1.551","article-title":"Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1","volume":"15","author":"Semenza","year":"1999","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"25733","DOI":"10.1074\/jbc.M002740200","article-title":"Hypoxia Inducible Factor-\u03b1 Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein","volume":"275","author":"Cockman","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/bbrc.1999.0878","article-title":"Characterization of an oxygen\/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins","volume":"260","author":"Srinivas","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1128\/MCB.18.7.4089","article-title":"Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300\/CREB binding protein","volume":"18","author":"Ebert","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"32253","DOI":"10.1074\/jbc.271.50.32253","article-title":"Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit","volume":"271","author":"Huang","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1073\/pnas.94.11.5667","article-title":"Activation of hypoxia-inducible factor 1alpha: Posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor","volume":"94","author":"Kallio","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1101\/gad.924501","article-title":"FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1101\/gad.991402","article-title":"FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor","volume":"16","author":"Lando","year":"2002","journal-title":"Genes Dev."},{"key":"ref_50","first-page":"1383","article-title":"Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas","volume":"60","author":"Frederick","year":"2000","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1101\/gad.12.23.3675","article-title":"A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice","volume":"12","author":"Holland","year":"1998","journal-title":"Genes Dev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1054\/bjoc.2001.1805","article-title":"Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway","volume":"84","author":"Clarke","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_53","first-page":"1541","article-title":"Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics","volume":"60","author":"Zhong","year":"2000","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2004.02.141","article-title":"The biology and clinical relevance of the PTEN tumor suppressor pathway","volume":"22","author":"Sansal","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.14.1.34","article-title":"Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha","volume":"14","author":"Ravi","year":"2000","journal-title":"Genes Dev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/ijc.30386","article-title":"FAT1 is a novel upstream regulator of HIF1\u03b1 and invasion of high grade glioma","volume":"139","author":"Madan","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-013-1081-y","article-title":"Geranylgeranyltransferase I regulates HIF-1\u03b1 promoting glioblastoma cell migration and invasion","volume":"112","author":"Zhou","year":"2013","journal-title":"J. Neurooncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/0008-5472.CAN-08-2158","article-title":"Alphavbeta3\/alphavbeta5 integrins-FAK-RhoB: A novel pathway for hypoxia regulation in glioblastoma","volume":"69","author":"Skuli","year":"2009","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"47808","DOI":"10.18632\/oncotarget.10029","article-title":"Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma","volume":"7","author":"Mao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Cloughesy, T.F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., and Youngkin, D. (2008). Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med., 5.","DOI":"10.1371\/journal.pmed.0050008"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study","volume":"23","author":"Galanis","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1078-0432.CCR-11-1558","article-title":"Antitumor activity of NVP-BKM120\u2014A selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells","volume":"18","author":"Koul","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"14687","DOI":"10.1038\/ncomms14687","article-title":"TRIB2 confers resistance to anti-cancer therapy by activating the serine\/threonine protein kinase AKT","volume":"8","author":"Hill","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/neuonc\/nos117","article-title":"Current clinical development of PI3K pathway inhibitors in glioblastoma","volume":"14","author":"Wen","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","article-title":"NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas","volume":"8","author":"Liu","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-16-1276","article-title":"PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models","volume":"23","author":"Lin","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Netland, I.A., F\u00f8rde, H.E., Sleire, L., Leiss, L., Rahman, M.A., Skeie, B.S., Gjerde, C.H., Enger, P.\u00d8., and Goplen, D. (2016). Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2712-4"},{"key":"ref_69","first-page":"2736","article-title":"Angiogenesis and prostate cancer: Identification of a molecular progression switch","volume":"61","author":"Huss","year":"2001","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8413032","DOI":"10.1155\/2016\/8413032","article-title":"The Tumorigenic Roles of the Cellular REDOX Regulatory Systems","volume":"2016","author":"Castaldo","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.cdd.4402307","article-title":"Mitochondrial complex III regulates hypoxic activation of HIF","volume":"15","author":"Klimova","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/19336918.2014.1000071","article-title":"Role of tenascins in the ECM of gliomas","volume":"9","author":"Faissner","year":"2015","journal-title":"Cell Adhes. Migr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.3892\/or.2015.3932","article-title":"mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma","volume":"33","author":"Bache","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_74","first-page":"413","article-title":"Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro","volume":"20","author":"Said","year":"2008","journal-title":"Oncol. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.radonc.2007.05.003","article-title":"Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1\u03b1 in human glioma in vitro and in vivo","volume":"83","author":"Said","year":"2007","journal-title":"Radiother. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/0008-5472.CAN-10-3061","article-title":"In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection","volume":"71","author":"Marotta","year":"2011","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/neuonc\/nos216","article-title":"Function of carbonic anhydrase IX in glioblastoma multiforme","volume":"14","author":"Proescholdt","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_78","first-page":"401","article-title":"Role of Proton Pumps in Tumorigenesis","volume":"82","author":"Kobliakov","year":"2017","journal-title":"Biochemistry"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s004180000181","article-title":"Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours","volume":"114","author":"Parkkila","year":"2000","journal-title":"Histochem. Cell Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"27799","DOI":"10.1074\/jbc.M800938200","article-title":"Biochemical Characterization of CA IX, One of the Most Active Carbonic Anhydrase Isozymes","volume":"283","author":"Hilvo","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejpb.2016.09.018","article-title":"Inhibition of carbonic anhydrase IX in glioblastoma multiforme","volume":"109","author":"Amiri","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2011.00049","article-title":"Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review","volume":"2","author":"Porporato","year":"2011","journal-title":"Front. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/07357907.2011.630050","article-title":"Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets","volume":"30","author":"Mao","year":"2012","journal-title":"Cancer Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1158\/0008-5472.CAN-11-1553","article-title":"Novel cryo-imaging of the glioma tumor microenvironment reveals migration and dispersal pathways in vivid three-dimensional detail","volume":"71","author":"Qutaish","year":"2011","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.18632\/oncotarget.6730","article-title":"EGFRvIII\/integrin \u03b23 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1073\/pnas.87.21.8602","article-title":"Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas","volume":"87","author":"Sugawa","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1073\/pnas.89.10.4309","article-title":"Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and\/or C-terminal tails","volume":"89","author":"Ekstrand","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","first-page":"2711","article-title":"Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme","volume":"48","author":"Malden","year":"1988","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnen\/63.7.700","article-title":"Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance","volume":"63","author":"Aldape","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrclinonc.2017.95","article-title":"Antibody-drug conjugates in glioblastoma therapy: The right drugs to the right cells","volume":"14","author":"Gan","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.canlet.2017.06.024","article-title":"Targeting EGFRvIII for glioblastoma multiforme","volume":"403","author":"Yang","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1128\/MCB.00015-07","article-title":"Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner","volume":"27","author":"Michiels","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1200\/JCO.2006.06.6514","article-title":"Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma","volume":"25","author":"Nabors","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.2007.14.1812","article-title":"Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012","volume":"26","author":"MacDonald","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/neuonc\/not058","article-title":"Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children\u2019s Oncology Group","volume":"15","author":"MacDonald","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","article-title":"Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme","volume":"26","author":"Reardon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"23401","DOI":"10.18632\/oncotarget.15581","article-title":"Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_99","first-page":"309","article-title":"Multi-step cascade of tumor cell metastasis","volume":"6","author":"Stracke","year":"1992","journal-title":"In Vivo"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2003.12.002","article-title":"Multiple connections link FAK to cell motility and invasion","volume":"14","author":"Schlaepfer","year":"2004","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/15216540050022386","article-title":"Cells on the move: A dialogue between polarization and motility","volume":"49","author":"Mira","year":"2000","journal-title":"IUBMB Life"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"40967","DOI":"10.1074\/jbc.M307380200","article-title":"Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis","volume":"278","author":"Zuurmond","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1158\/0008-5472.CAN-08-4859","article-title":"The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells","volume":"69","author":"Ulrich","year":"2009","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"12722","DOI":"10.1074\/jbc.M112.447631","article-title":"Stiff Collagen Matrices Increase Tumorigenic Prolactin Signaling in Breast Cancer Cells","volume":"288","author":"Barcus","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","article-title":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","volume":"139","author":"Levental","year":"2009","journal-title":"Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.biopha.2017.04.023","article-title":"PLOD2 in cancer research","volume":"90","author":"Du","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/2159-8290.CD-13-0118","article-title":"Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis","volume":"3","author":"Zhang","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.matbio.2005.04.002","article-title":"Minoxidil exerts different inhibitory effects on gene expression of lysyl hydroxylase 1, 2, and 3: Implications for collagen cross-linking and treatment of fibrosis","volume":"24","author":"Zuurmond","year":"2005","journal-title":"Matrix Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ptr.3586","article-title":"Berberine inhibits pulmonary metastasis through down-regulation of MMP in metastatic B16F-10 melanoma cells","volume":"26","author":"Hamsa","year":"2012","journal-title":"Phytother. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/08923970802278276","article-title":"Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, NM23 and cytokines in lung tissues of C57BL\/6 mice","volume":"30","author":"Guruvayoorappan","year":"2008","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/1534735407305978","article-title":"Beta-carotene inhibits tumor-specific angiogenesis by altering the cytokine profile and inhibits the nuclear translocation of transcription factors in B16F-10 melanoma cells","volume":"6","author":"Guruvayoorappan","year":"2007","journal-title":"Integr. Cancer Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/onc.2013.128","article-title":"Multilayer control of the EMT master regulators","volume":"33","author":"Zheng","year":"2014","journal-title":"Oncogene"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1101\/gad.276304","article-title":"Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation","volume":"18","author":"Timmerman","year":"2004","journal-title":"Genes Dev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/bjc.2017.157","article-title":"CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells","volume":"117","author":"Maciaczyk","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI86114","article-title":"RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation","volume":"126","author":"Xie","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/ncb1998","article-title":"The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs","volume":"11","author":"Wellner","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/emmm.201302827","article-title":"The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance","volume":"5","author":"Siebzehnrubl","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.01.010","article-title":"Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1\u03b1-ZEB1 axis","volume":"359","author":"Joseph","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bpa.12240","article-title":"ZEB1 Promotes Invasion in Human Fetal Neural Stem Cells and Hypoxic Glioma Neurospheres","volume":"25","author":"Kahlert","year":"2015","journal-title":"Brain Pathol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/ncb858","article-title":"Activation of the repulsive receptor Roundabout inhibits N-cadherin-mediated cell adhesion","volume":"4","author":"Rhee","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.4161\/cc.7.14.6324","article-title":"TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development","volume":"7","author":"Yang","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1038\/onc.2010.92","article-title":"TWISTing an embryonic transcription factor into an oncoprotein","volume":"29","author":"Ansieau","year":"2010","journal-title":"Oncogene"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-1119(01)00893-9","article-title":"A Twist in fate: Evolutionary comparison of Twist structure and function","volume":"287","author":"Castanon","year":"2002","journal-title":"Gene"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1158\/0008-5472.CAN-16-2797","article-title":"TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis","volume":"77","author":"Malek","year":"2017","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1242\/jcs.196790","article-title":"Aurora A-Twist1 axis promotes highly aggressive phenotypes in pancreatic carcinoma","volume":"130","author":"Wang","year":"2017","journal-title":"J. Cell Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/jclinpath-2015-202868","article-title":"Twist predicts poor outcome of patients with astrocytic glioma","volume":"68","author":"Nordfors","year":"2015","journal-title":"J. Clin. Pathol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ncb1691","article-title":"Direct regulation of TWIST by HIF-1alpha promotes metastasis","volume":"10","author":"Yang","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1476-4598-9-194","article-title":"TWIST1 promotes invasion through mesenchymal change in human glioblastoma","volume":"9","author":"Mikheeva","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1593\/neo.04352","article-title":"TWIST is expressed in human gliomas and promotes invasion","volume":"7","author":"Elias","year":"2005","journal-title":"Neoplasia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ncb3090","article-title":"Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth","volume":"17","author":"Zhou","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/onc.2013.305","article-title":"Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice","volume":"33","author":"Serres","year":"2014","journal-title":"Oncogene"},{"key":"ref_132","first-page":"1349","article-title":"SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA","volume":"29","author":"Kunigal","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Yang, H.W., Menon, L.G., Black, P.M., Carroll, R.S., and Johnson, M.D. (2010). SNAI2\/Slug promotes growth and invasion in human gliomas. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-301"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/0008-5472.CAN-10-2330","article-title":"Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis","volume":"71","author":"Casas","year":"2011","journal-title":"Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1158\/0008-5472.CAN-12-1943","article-title":"Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target","volume":"73","author":"Soroceanu","year":"2013","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Cruickshanks, N., Zhang, Y., Yuan, F., Pahuski, M., Gibert, M., and Abounader, R. (2017). Role and Therapeutic Targeting of the HGF\/MET Pathway in Glioblastoma. Cancers, 9.","DOI":"10.3390\/cancers9070087"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Da Silva, R., Uno, M., Marie, S.K.N., and Oba-Shinjo, S.M. (2015). LOX expression and functional analysis in astrocytomas and impact of IDH1 mutation. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119781"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/1541-7786.MCR-11-0457","article-title":"Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo","volume":"10","author":"Kaur","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1523\/JNEUROSCI.0968-09.2009","article-title":"BMI1 sustains human glioblastoma multiforme stem cell renewal","volume":"29","author":"Abdouh","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/labinvest.3700482","article-title":"Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: Implications for angiogenesis and glioma cell invasion","volume":"86","author":"Zagzag","year":"2006","journal-title":"Lab. Investig."},{"key":"ref_141","first-page":"102","article-title":"Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma","volume":"6","author":"Rempel","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1038\/sj.onc.1209302","article-title":"CXCR4 expression mediates glioma cell invasiveness","volume":"25","author":"Ehtesham","year":"2006","journal-title":"Oncogene"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2005.05.011","article-title":"SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion","volume":"236","author":"Hong","year":"2006","journal-title":"Cancer Lett."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment","volume":"107","author":"Burger","year":"2006","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"14153","DOI":"10.1074\/jbc.M010429200","article-title":"Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor","volume":"276","author":"Gerlach","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1172\/JCI40283","article-title":"Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice","volume":"120","author":"Kioi","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13046-016-0326-y","article-title":"Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model","volume":"35","author":"Mercurio","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/abbs\/gmv095","article-title":"Critical roles of chemokine receptor CCR5 in regulating glioblastoma proliferation and invasion","volume":"47","author":"Zhao","year":"2015","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.3892\/or.2016.5171","article-title":"Hypoxia and macrophages promote glioblastoma invasion by the CCL4-CCR5 axis","volume":"36","author":"Wang","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1084\/jem.186.8.1383","article-title":"Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4","volume":"186","author":"Schols","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/095632020501600601","article-title":"CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection","volume":"16","author":"Westby","year":"2005","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(08)80048-3","article-title":"Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection","volume":"30","author":"Fung","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/14728222.2014.949238","article-title":"The potential to target CCL5\/CCR5 in breast cancer","volume":"18","author":"Xolalpa","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"48335","DOI":"10.18632\/oncotarget.10227","article-title":"Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation","volume":"7","author":"Tanabe","year":"2016","journal-title":"Oncotarget"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e1150398","DOI":"10.1080\/2162402X.2016.1150398","article-title":"Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs","volume":"5","author":"Halvorsen","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","article-title":"Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients","volume":"29","author":"Halama","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11060-015-1996-6","article-title":"Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells","volume":"126","author":"Kast","year":"2016","journal-title":"J. Neurooncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10143-007-0070-z","article-title":"Identification of hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA microarray analysis","volume":"30","author":"Ragel","year":"2007","journal-title":"Neurosurg. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1476-4598-9-133","article-title":"Knock down of HIF-1\u03b1 in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres","volume":"9","author":"Zavadil","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1593\/neo.131440","article-title":"Cyclin G2 promotes hypoxia-driven local invasion of glioblastoma by orchestrating cytoskeletal dynamics","volume":"15","author":"Fujimura","year":"2013","journal-title":"Neoplasia"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"27449","DOI":"10.1074\/jbc.M111693200","article-title":"Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B\u2019 subunits in active complexes and induces nuclear aberrations and a G1\/S phase cell cycle arrest","volume":"277","author":"Bennin","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1016\/j.yexcr.2006.09.023","article-title":"Cyclin G2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a p53-dependent cell cycle arrest","volume":"312","author":"Dallapiazza","year":"2006","journal-title":"Exp. Cell Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/0008-5472.CAN-04-3376","article-title":"PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma","volume":"65","author":"Rong","year":"2005","journal-title":"Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1158\/0008-5472.CAN-06-0346","article-title":"Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms","volume":"66","author":"Rong","year":"2006","journal-title":"Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/01.ATV.0000171155.05809.bf","article-title":"Signaling of the tissue factor coagulation pathway in angiogenesis and cancer","volume":"25","author":"Belting","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X","article-title":"Expression of tissue factor correlates with grade of malignancy in human glioma","volume":"77","author":"Hamada","year":"1996","journal-title":"Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Harter, P.N., D\u00fctzmann, S., Drott, U., Zachskorn, C., Hattingen, E., Capper, D., Gessler, F., Senft, C., Seifert, V., and Plate, K.H. (2013). Anti-tissue factor (TF9\u201310H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model. Neuropathology, 33.","DOI":"10.1111\/neup.12018"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1161\/ATVBAHA.108.177428","article-title":"Tissue factor and PAR2 signaling in the tumor microenvironment","volume":"29","author":"Schaffner","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2008-1079254","article-title":"Tissue factor and protease-activated receptor signaling in cancer","volume":"34","author":"Schaffner","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.neuroscience.2009.11.049","article-title":"Inhibition of tissue factor\/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells","volume":"165","author":"Gessler","year":"2010","journal-title":"Neuroscience"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/1078-0432.CCR-07-1990","article-title":"Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy","volume":"14","author":"Wykosky","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1541-7786.MCR-05-0056","article-title":"EphA2 as a novel molecular marker and target in glioblastoma multiforme","volume":"3","author":"Wykosky","year":"2005","journal-title":"Mol. Cancer Res."},{"key":"ref_173","first-page":"151","article-title":"Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients","volume":"19","author":"Wang","year":"2008","journal-title":"Oncol. Rep."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1541-7786.MCR-08-0582","article-title":"Hsp90 is an essential regulator of EphA2 receptor stability and signaling: Implications for cancer cell migration and metastasis","volume":"7","author":"Annamalai","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","article-title":"EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt","volume":"16","author":"Miao","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/35000008","article-title":"Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation","volume":"2","author":"Miao","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2005.07.005","article-title":"A conditional feedback loop regulates Ras activity through EphA2","volume":"8","author":"Macrae","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Gopal, U., Bohonowych, J.E., Lema-Tome, C., Liu, A., Garrett-Mayer, E., Wang, B., and Isaacs, J.S. (2011). A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017649"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1016\/j.febslet.2007.05.040","article-title":"Inhibitors of the heat shock response: Biology and pharmacology","volume":"581","author":"Powers","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: Are we there yet?","volume":"18","author":"Neckers","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/ijo.2014.2399","article-title":"HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review)","volume":"45","author":"Wang","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/0008-5472.CAN-09-2654","article-title":"Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness","volume":"70","author":"Chigurupati","year":"2010","journal-title":"Cancer Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1007\/s13277-015-3577-x","article-title":"Gene expressions of TRP channels in glioblastoma multiforme and relation with survival","volume":"36","author":"Alptekin","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev.biochem.75.103004.142819","article-title":"TRP channels","volume":"76","author":"Venkatachalam","year":"2007","journal-title":"Annu. Rev. Biochem."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/6\/4\/45\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:50:48Z","timestamp":1760208648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/6\/4\/45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":184,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["cells6040045"],"URL":"https:\/\/doi.org\/10.3390\/cells6040045","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]}}}